We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+13.64%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.46B
AUM Growth
+$126M
(+5.4%)
Cap. Flow
-$103M
Cap. Flow
% of AUM
-4.19%
Top 10 Holdings %
Top 10 Hldgs %
40.31%
Holding
211
New
10
Increased
47
Reduced
69
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$23.4M |
| 2 |
Merck
MRK
|
+$20M |
| 3 |
Welltower
WELL
|
+$14.4M |
| 4 |
Cigna
CI
|
+$9.62M |
| 5 |
Eli Lilly
LLY
|
+$9.59M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$25.4M |
| 2 |
Johnson & Johnson
JNJ
|
+$18M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$15M |
| 4 |
AbbVie
ABBV
|
+$14.1M |
| 5 |
Viatris
VTRS
|
+$13.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.43% |
| 2 | Real Estate | 2.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Labcorp
LH
$25.9B
| $6.99M | 0.28% |
53,145
+19,273
| +57% | +$2.37M |
|
|
ABMD
77
DELISTED
Abiomed Inc
ABMD
| $6.85M | 0.28% |
23,986
+11,636
| +94% | +$3.87M |
|
78
Centene
CNC
$30.1B
| $6.81M | 0.28% |
128,295
-205,443
| -62% | -$12.5M |
|
|
LTC
79
LTC Properties
LTC
$2.06B
| $6.66M | 0.27% |
145,421
-33,202
| -19% | -$1.49M |
|
|
ICPT
80
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $6.63M | 0.27% |
59,275
+45,927
| +344% | +$5.02M |
|
81
CRISPR Therapeutics
CRSP
$4.77B
| $6.37M | 0.26% |
178,348
| – | – |
|
82
Cencora
COR
$60.7B
| $6.3M | 0.26% |
79,226
-32,581
| -29% | -$2.62M |
|
83
Ventas
VTR
$47.1B
| $6.29M | 0.26% |
98,496
| – | – |
|
84
Agios Pharmaceuticals
AGIO
$1.95B
| $6.19M | 0.25% |
91,776
+42,751
| +87% | +$2.49M |
|
85
Steris
STE
$22.5B
| $6.15M | 0.25% |
48,003
| – | – |
|
|
MPT
86
Medical Properties Trust
MPT
$2.81B
| $6.04M | 0.25% |
326,063
-87,746
| -21% | -$1.56M |
|
87
Quest Diagnostics
DGX
$25.9B
| $5.98M | 0.24% |
66,500
| – | – |
|
|
GWPH
88
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $5.88M | 0.24% |
34,891
-28,454
| -45% | -$4.23M |
|
|
DOC
89
DELISTED
PHYSICIANS REALTY TRUST
DOC
| $5.72M | 0.23% |
303,908
-87,108
| -22% | -$1.55M |
|
|
LKFT
90
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
| $5.71M | 0.23% |
48,525
-51,290
| -51% | -$5.17M |
|
|
IMMU
91
DELISTED
Immunomedics Inc
IMMU
| $5.53M | 0.22% |
287,687
-143,840
| -33% | -$2.32M |
|
92
Ultragenyx Pharmaceutical
RARE
$2.56B
| $5.34M | 0.22% |
76,958
| – | – |
|
|
WCG
93
DELISTED
Wellcare Health Plans, Inc.
WCG
| $5.2M | 0.21% |
19,286
+6,286
| +48% | +$1.62M |
|
94
Acadia Healthcare
ACHC
$2.62B
| $5.08M | 0.21% |
173,155
| – | – |
|
|
ZGNX
95
DELISTED
Zogenix, Inc.
ZGNX
| $4.94M | 0.2% |
89,762
-21,263
| -19% | -$1.01M |
|
96
United Therapeutics
UTHR
$26.2B
| $4.84M | 0.2% |
41,261
| – | – |
|
97
AnaptysBio
ANAB
$1.63B
| $4.81M | 0.2% |
65,845
| – | – |
|
|
MRUS
98
DELISTED
Merus
MRUS
| $4.69M | 0.19% |
317,671
-50,000
| -14% | -$639K |
|
|
GBT
99
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $4.55M | 0.18% |
85,988
-7,936
| -8% | -$390K |
|
100
Bio-Techne
TECH
$11.2B
| $4.31M | 0.18% |
+86,804
| New | +$3.91M |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q1 2019 Portfolio in Review
As of Q1 2019, Tekla Capital Management held 211 positions worth $2.46B, up 5.4% from $2.34B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Tekla Capital Management withdrew a net $103M in Q1 2019, closing 17 positions and reducing 69 holdings. Its most notable exit was Shire pic, an estimated $6.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Real Estate.
Against the trend, Tekla Capital Management opened a new position in Bio-Techne worth $4.31M.
- Tekla Capital Management's largest Q1 2019 buy was Bio-Techne: 86,804 shares worth $4.31M.
- Tekla Capital Management added most to Pfizer in Q1 2019, an estimated $23.4M increase.
- Tekla Capital Management's biggest Q1 2019 reduction was Biogen, cutting an estimated $25.4M.
- Tekla Capital Management fully exited Shire pic in Q1 2019, selling an estimated $6.3M.
- Tekla Capital Management's ten largest holdings make up 40% of its $2.46B portfolio in Q1 2019.
- Tekla Capital Management opened 10 new positions and closed 17 in Q1 2019.
- Tekla Capital Management's portfolio value rose 5.4% quarter-over-quarter to $2.46B.
Based on Tekla Capital Management's 13F filing for Q1 2019, filed 14 May 2019.